PEPTIDE CORTEXThe library
Dosing referencenever gated · no calculator

What the label or the trial says.

Per peptide, the figure the drug label or the published trial gives, with the source beside it. Under many rows, the full protocols on file — starting dose, escalation, target, cycle — each badged FDA label, clinical trial or community protocol, and each linked to where it came from. Where there is nothing to cite, the row says so.

Look up —
All 130With a published figure 29Points to a label 24No human dose 77
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

Peptide · gradeWhat the label or trial saysSource
Afamelanotidegrade A16 mg subcutaneous implant every 2 monthsFDA label
Scenesse
Botulinum Toxingrade ADose is specific to indication and expressed in Units that are NOT interchangeable between botulinum toxin products. The label gives, for example, 100 Units total for overactive bladder across 20 detrusor sites, and 4–8 Units/kg to a maximum of 300 Units for paediatric lower-limb spasticity. Administration is a clinical procedure, not a self-directed one.FDA label
Botox, onabotulinumtoxinA
Bremelanotidegrade A1.75 mg SC as needed ≥45 min before; max 1 dose/24h; max 8 doses/monthFDA label
Vyleesi
Protocols · 2 · label / community
FDA labelVyleesi (premenopausal women with acquired, generalized HSDD)
As needed, at least 45 minutes before anticipated sexual activity
Start: 1.75 mg SC as needed
Then: None; fixed dose
Target: 1.75 mg SC as needed
Max: No more than one dose within 24 hours; more than 8 doses per month not recommended
Community protocol — not clinically establishedCommunity guide
On demand
Start: 1.75 mg (mirrors the label)
Then: None ("fixed on-demand protocol")
Target: 1.75 mg on demand
Cycle: On-demand; label limits of 1 per 24 h and 8 per month
Cagrilintidegrade DTrial doses (not approved): phase 2 arms of 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly for 26 weeks; 2.4 mg once weekly as the cagrilintide-alone arm of phase 3 REDEFINE 1.Published trial
Trial arms · not approved
Protocols · 3 · trial / community
Clinical trialPhase 2 dose-finding (Lau, Lancet 2021)
Once weekly, 26 weeks
Start: Not given in the abstract
Then: Dose-escalation period of up to 6 weeks; step sizes not published in the abstract
Target: Arms: 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly. Weight loss 6.0% to 10.8% vs 3.0% placebo.
Max: 4.5 mg weekly (maximum studied)
Clinical trialREDEFINE 1 cagrilintide-alone arm (NEJM 2025)
Once weekly, 68 weeks
Start: Not described separately for the monotherapy arm
Then: Not described separately for the monotherapy arm
Target: 2.4 mg once weekly: -11.8% weight change (trial-product estimand)
Community protocol — not clinically establishedCommunity guide
Once weekly
Start: 0.25 mg/week, weeks 1-4
Then: 0.5 mg weeks 5-8, 1.0 mg weeks 9-12, 1.7 mg weeks 13-16, 2.4 mg from week 17. Copies the CagriSema/semaglutide ladder; no monotherapy trial published it.
Target: 2.4 mg weekly
Cycle: Short 16 weeks, standard 26-32 weeks, long 68 weeks
CagriSemagrade DTrial doses (not approved): REDEFINE 1 started at 0.25 mg of each drug and increased every 4 weeks to cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly by week 16, then 52 weeks of maintenance.Published trial
Trial arms · not approved
Protocols · 3 · trial / community
Clinical trialREDEFINE 1 (NEJM 2025)
Once weekly, 68 weeks
Start: 0.25 mg of each drug
Then: Increased every 4 weeks until 2.4 mg of each drug was reached by week 16; investigators could delay escalation or reduce the dose for adverse effects
Target: Cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly, 52-week maintenance. Weight change -20.4% (treatment-policy) vs -3.0% placebo.
Clinical trialREDEFINE 2, type 2 diabetes (NEJM 2025)
Once weekly, 68 weeks
Start: Not given in the summary
Then: Not given in the summary
Target: CagriSema 2.4/2.4 mg weekly. Weight change -15.7% vs -3.1% placebo.
Community protocol — not clinically establishedCommunity guide
Once weekly
Start: 0.25 mg of each component weekly
Then: 0.25/0.25 weeks 1-4, 0.5/0.5 weeks 5-8, 1.0/1.0 weeks 9-12, 1.7/1.7 weeks 13-16, 2.4/2.4 mg from week 17. The intermediate steps are the guide's; the NEJM text says only "increased every 4 weeks".
Target: Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly
Cycle: "Standard research cycle: 12-24 weeks" (no trial basis); trial-mirroring 68 weeks
Degarelixgrade A240 mg SC loading dose, then 80 mg SC every 28 daysFDA label
Firmagon
Elamipretidegrade A40 mg SC once daily (per labelled indication)FDA label
per labelled indication
Protocols · 3 · label / trial / community
FDA labelForzinity (Barth syndrome, accelerated approval 2025-09-19)
Once daily, same time each day
Start: 40 mg SC once daily (patients at least 30 kg)
Then: None
Target: 40 mg SC once daily
Clinical trialTAZPOWER, Barth syndrome (phase 2/3)
Once daily
Start: 40 mg SC daily
Then: None
Target: 40 mg SC daily, 12-week randomised crossover periods, then open-label extension
Community protocol — not clinically establishedCommunity guide (as SS-31)
Once daily
Start: "Micro-start" 0.1-1 mg daily
Then: Common cluster 1-5 mg daily; "guide-page standard" 5-10 mg; "performance-oriented" 10-20 mg daily
Target: Varies 1-20 mg/day
Cycle: 1-5 mg cluster run for 4-8 weeks
Enfuvirtidegrade A90 mg SC twice dailyFDA label
Fuzeon
Gonadorelingrade ADiagnostic: 100 mcg SC or IV; other regimens per prescribing informationPI
Product prescribing information
Icatibantgrade A30 mg SC as a single dose; may repeat per prescribing informationPI
Product prescribing information
L-Carnitinegrade AThe FDA-approved oral dose for carnitine deficiency is 990 mg two or three times daily using 330 mg tablets; oral solution is 1–3 g/day for a 50 kg patient, started at 1 g/day and titrated against tolerance.FDA label
levocarnitine, Carnitor
Lanreotidegrade A90-120 mg by deep subcutaneous injection every 4 weeksFDA label
Somatuline Depot
Leuprolidegrade A7.5 mg IM monthly (depot); other depot strengths per prescribing informationPI
Product prescribing information
Linaclotidegrade A72-290 mcg orally once daily depending on indicationFDA label
Linzess
Liraglutidegrade A0.6 mg daily titration up to 3 mg daily (Saxenda)FDA label
Saxenda
Protocols · 1 · label
FDA labelSaxenda
Once daily
Start: 0.6 mg daily, week 1
Then: 1.2 mg week 2, 1.8 mg week 3, 2.4 mg week 4
Target: 3 mg daily from week 5 (adults and pediatric patients)
Max: 3 mg daily. Adults who cannot tolerate 3 mg: discontinue.
Octreotidegrade AImmediate release 50-100 mcg SC two to three times daily; LAR 20 mg IM every 4 weeksFDA label
Sandostatin
Orforgliprongrade AOral tablet once daily: 0.8 mg for at least 30 days, then 2.5 mg, then 5.5 mg; optionally 9 mg, 14.5 mg and 17.2 mg, each step after at least 30 days, by response and tolerability. Maximum 17.2 mg daily, or 9 mg daily with a strong CYP3A4 inhibitor. Approved by the FDA in April 2026 for chronic weight management in adults with obesity, or overweight with a weight-related condition.FDA label
Foundayo, oral GLP-1
Protocols · 1 · label
FDA labelFoundayo (FDA approval 2026-04-01)
Once daily, with or without food
Start: 0.8 mg once daily for at least 30 days
Then: 2.5 mg for at least 30 days, then 5.5 mg; then optionally 9 mg, 14.5 mg and 17.2 mg, each after at least 30 days, based on treatment response and tolerability
Target: 5.5, 9 or 17.2 mg once daily (the randomised maintenance doses)
Max: 17.2 mg once daily; 9 mg once daily with a strong CYP3A4 inhibitor
Plecanatidegrade A3 mg orally once daily; 6 mg for IBS-C per prescribing informationPI
Product prescribing information
Pramlintidegrade AT1D: start 15 mcg pre-meals; titrate; T2D: start 60 mcg pre-meals → 120 mcgFDA label
Symlin
Retatrutidegrade DTrial doses (not approved): phase 2 (Jastreboff, NEJM 2023) arms of 1, 4, 8 or 12 mg once weekly — the 1 mg arm stayed at 1 mg, the others started at 2 or 4 mg with escalation every 4 weeks; phase 3 TRIUMPH-1 started at 2 mg and escalated every 4 weeks to 4, 9 or 12 mg once weekly.Published trial
Trial arms · not approved
Protocols · 3 · trial / community
Clinical trialPhase 2 (Jastreboff, NEJM 2023)
Once weekly, 48 weeks
Start: Arms of 4 mg or more started at 2 mg or 4 mg; a 1 mg arm was fixed
Then: Gradual dose escalation every 4 weeks for up to 12 weeks
Target: Arms: 1, 4, 8 or 12 mg once weekly. 48-week weight change -8.7% (1 mg) to -24.2% (12 mg) vs -2.1% placebo.
Max: 12 mg weekly (maximum studied)
Clinical trialPhase 3 TRIUMPH-1 (Lilly topline, 2026-05-21)
Once weekly, 80 weeks
Start: 2 mg
Then: Started at 2 mg once weekly, stepping up every 4 weeks to the target: 4 mg arm via one step at 2 mg; 9 mg arm via steps at 2, 4 and 6 mg; 12 mg arm via steps at 2, 4, 6 and 9 mg
Target: 4 mg, 9 mg or 12 mg once weekly. 80-week weight loss -19.0%, -25.9%, -28.3% vs -2.2% placebo.
Community protocol — not clinically establishedCommunity guide
Once weekly
Start: 2 mg weekly, weeks 1-4
Then: 4 mg weeks 5-8, 6 mg weeks 9-12, 9 mg weeks 13-16, 12 mg from week 17. The Lilly TRIUMPH-1 release lists the same 2, 4, 6 and 9 mg steps on the way to 12 mg.
Target: 4, 9 or 12 mg "depending on trial arm"
Cycle: "Phase 3 studies ran 68-80 weeks"
Semaglutidegrade AInjection: 0.25 mg weekly, stepped up every 4 weeks through 0.5, 1 and 1.7 mg to a maintenance of 1.7 or 2.4 mg weekly; maximum 7.2 mg weekly for adults who have tolerated 2.4 mg for at least 4 weeks (Wegovy, label 06/2026). Wegovy tablets: 1.5 mg, then 4 mg, then 9 mg, then 25 mg once daily, in 30-day steps.FDA label
Wegovy, label 06/2026
Protocols · 4 · label / community
FDA labelWegovy injection (label revised 06/2026)
Once weekly
Start: 0.25 mg once weekly, weeks 1-4
Then: 0.5 mg weeks 5-8, 1 mg weeks 9-12, 1.7 mg weeks 13-16. If a dose is not tolerated during escalation, consider delaying escalation for 4 weeks.
Target: Adult weight reduction: 1.7 mg or 2.4 mg (recommended) once weekly
Max: 7.2 mg once weekly (adult weight reduction only, after tolerating 2.4 mg for at least 4 weeks, when additional weight reduction is clinically indicated; supplied as Wegovy HD 7.2 mg/0.75 mL)
FDA labelWegovy tablets (label revised 06/2026)
Once daily, on an empty stomach with up to 4 oz water, then wait 30 minutes before food or other drinks
Start: 1.5 mg once daily, days 1-30
Then: 4 mg once daily days 31-60, 9 mg once daily days 61-90
Target: 25 mg once daily (maintenance), from day 91
FDA labelOzempic injection (type 2 diabetes)
Once weekly
Start: 0.25 mg once weekly for 4 weeks (initiation only, not effective for glycemic control)
Then: 0.5 mg once weekly; after at least 4 weeks on 0.5 mg, may go to 1 mg; after at least 4 weeks on 1 mg, to 2 mg
Target: 0.5 mg, 1 mg or 2 mg once weekly
Max: 2 mg once weekly
Community protocol — not clinically establishedCommunity guide
Once weekly
Start: 0.25 mg weekly, described as "Starting dose for tolerability only. Not a therapeutic dose."
Then: 0.25 then 0.5, 1.0, 1.7 and 2.4 mg, 4 weeks per step, with the option to delay
Target: 2.4 mg weekly (the page does not mention the 7.2 mg label dose)
Cycle: About 16 weeks to reach maintenance, then ongoing
Setmelanotidegrade A2-3 mg SC once daily following titration (per prescribing information)PI
Product prescribing information
Survodutidegrade DTrial doses (not approved): phase 2 arms of 0.6, 2.4, 3.6 or 4.8 mg once weekly after a 20-week escalation; phase 3 SYNCHRONIZE-1 arms of up to 3.6 mg or up to 6.0 mg once weekly.Published trial
Trial arms · not approved
Protocols · 3 · trial / community
Clinical trialPhase 2 (le Roux, Lancet Diabetes Endocrinol 2024)
Once weekly, 46 weeks
Start: Not given in the abstract
Then: 20 weeks dose escalation; step sizes not in the abstract
Target: Arms: 0.6, 2.4, 3.6 or 4.8 mg once weekly, 26 weeks maintenance. Weight change -6.2% to -14.9% vs -2.8% placebo.
Clinical trialPhase 3 SYNCHRONIZE-1 (NEJM 2026)
Once weekly, 76 weeks
Start: Escalation schedule not retrieved
Then: Dose adjusted up to the arm maximum; schedule not retrieved
Target: Up to 3.6 mg or up to 6.0 mg once weekly. Primary result (treatment-regimen estimand): body weight -12% (3.6 mg) and -13% (6.0 mg) vs -5% placebo at week 76. On the efficacy estimand, weight loss up to 16.6% vs 3.2% placebo.
Max: 6.0 mg weekly (maximum studied)
Community protocol — not clinically establishedCommunity guide
Once weekly
Start: "Phase 2 trial began at 0.6 mg weekly"
Then: "20-week escalation" in phase 2; phase 3 was "slower and more flexible"
Target: 2.4-3.6 mg
Cycle: 46 weeks (phase 2); 76 weeks (phase 3)
Teriparatide (Forteo)grade A20 mcg SC once dailyFDA label
Forteo
Tesamorelingrade AEgrifta SV: 1.4 mg SC once daily; Egrifta WR: 1.28 mg SC once dailyFDA label
Egrifta SV
Protocols · 4 · label / trial / community
FDA labelEgrifta WR (HIV lipodystrophy abdominal fat)
Once daily
Start: 1.28 mg once daily; no titration
Then: None
Target: 1.28 mg once daily
Max: 1.28 mg daily
FDA labelEgrifta SV (HIV lipodystrophy abdominal fat)
Once daily
Start: 1.4 mg (0.35 mL of reconstituted solution) once daily; no titration
Then: None
Target: 1.4 mg once daily
Clinical trialPhase 3 (Falutz, NEJM 2007)
Once daily, 26 weeks
Start: 2 mg daily
Then: None
Target: 2 mg daily (original formulation, before SV and WR)
Community protocol — not clinically establishedCommunity guide
Once daily
Start: Full dose from day one: 2 mg for research vials; "No titration required"
Then: None
Target: 2 mg daily for research vials, mirroring the original phase 3
Cycle: Standard 26 weeks, extended 52 weeks
Tesofensinegrade BNot FDA-approved. Approved in Mexico since 2023 as Nupenta (monotherapy) and Tesomet (with metoprolol). Phase 3 planning used 0.25 and 0.5 mg/day orally.Regional label
monotherapy
Tirzepatidegrade A2.5 mg weekly start → 5 mg; may increase by 2.5 mg q≥4 weeks; max 15 mg weeklyFDA label
Zepbound
Protocols · 3 · label / community
FDA labelZepbound (label revised 02/2026)
Once weekly
Start: 2.5 mg once weekly for 4 weeks (initiation; not approved as a maintenance dosage)
Then: Increase in 2.5 mg increments after at least 4 weeks on the current dose (5, 7.5, 10, 12.5, 15 mg)
Target: Weight reduction and long-term maintenance: 5 mg, 10 mg or 15 mg once weekly. Obstructive sleep apnea: 10 mg or 15 mg once weekly.
Max: 15 mg once weekly for all indications
FDA labelMounjaro (type 2 diabetes)
Once weekly
Start: 2.5 mg once weekly
Then: 5 mg after 4 weeks; if more glycemic control is needed, increase in 2.5 mg steps after at least 4 weeks on the current dose
Target: Per glycemic response
Max: 15 mg once weekly
Community protocol — not clinically establishedCommunity guide
Once weekly
Start: 2.5 mg weekly for 4 weeks
Then: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, with at least 4 weeks between steps
Target: 5, 10 or 15 mg; the page says "most users stabilize at intermediate doses without reaching maximum"
Cycle: At least 24 weeks to climb the full ladder, then ongoing
Triptorelingrade A3.75 mg IM monthly; longer-acting depots per prescribing informationPI
Product prescribing information
Vitamin B12grade AFor pernicious anaemia the labelled regimen is 30–50 mcg intramuscularly or subcutaneously daily for at least two weeks to a total of 1,000–5,000 mcg, then 100 mcg monthly as maintenance. Higher single doses are common in practice.FDA label
cyanocobalamin

No body weight, no goals, no calculator: the same text for every reader. A figure without its source is indistinguishable from a recommendation, so every row and every protocol carries one. Community protocols are what guides and vendors publish, not what any trial established. Where nothing can be cited, the row says so.